Traversa Sergio's Form 4 filing
Relmada Therapeutics, Inc. (RLMD) · filed May 20, 2025
- Accession no.
- 0001213900-25-046085
- Filed
- May 20, 2025, 6:01 PM ET
- Trade date
- May 16-20, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $174.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Traversa SergioCIK 0001565832 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2025 | Common Stock | PPurchaseAcquired | +172,314 | $0.4496 | +$77,472.37 | 556,338 | Direct | |
| May 19, 2025 | Common Stock | PPurchaseAcquired | +30,000 | $0.4998 | +$14,994 | 586,338 | Direct | |
| May 20, 2025 | Common Stock | PPurchaseAcquired | +147,686 | $0.5569 | +$82,246.33 | 734,024 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.